Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;39(1):25-61.
doi: 10.1007/s40273-020-00980-w. Epub 2020 Nov 26.

Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

Affiliations
Review

Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

Ruth A Lewis et al. Pharmacoeconomics. 2021 Jan.

Abstract

Sequential use of alternative treatments for chronic conditions represents a complex intervention pathway; previous treatment and patient characteristics affect both the choice and effectiveness of subsequent treatments. This paper critically explores the methods for quantitative evidence synthesis of the effectiveness of sequential treatment options within a health technology assessment (HTA) or similar process. It covers methods for developing summary estimates of clinical effectiveness or the clinical inputs for the cost-effectiveness assessment and can encompass any disease condition. A comprehensive review of current approaches is presented, which considers meta-analytic methods for assessing the clinical effectiveness of treatment sequences and decision-analytic modelling approaches used to evaluate the effectiveness of treatment sequences. Estimating the effectiveness of a sequence of treatments is not straightforward or trivial and is severely hampered by the limitations of the evidence base. Randomised controlled trials (RCTs) of sequences were often absent or very limited. In the absence of sufficient RCTs of whole sequences, there is no single best way to evaluate treatment sequences; however, some approaches could be re-used or adapted, sharing ideas across different disease conditions. Each has advantages and disadvantages, and is influenced by the evidence available, extent of treatment sequences (number of treatment lines or permutations), and complexity of the decision problem. Due to the scarcity of data, modelling studies applied simplifying assumptions to data on discrete treatments. A taxonomy for all possible assumptions was developed, providing a unique resource to aid the critique of existing decision-analytic models.

PubMed Disclaimer

Conflict of interest statement

RL, DH, AJS, and CW have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Flow diagram showing the number of references identified, publications retrieved, and studies included in the methodology review

Similar articles

Cited by

  • Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.
    de Groot S, Blommestein HM, Leeneman B, Uyl-de Groot CA, Haanen JBAG, Wouters MWJM, Aarts MJB, van den Berkmortel FWPJ, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, van Not OJ, van der Veldt AAM, Suijkerbuijk KPM, van Baal PHM. de Groot S, et al. Med Decis Making. 2025 Apr;45(3):302-317. doi: 10.1177/0272989X251319338. Epub 2025 Feb 22. Med Decis Making. 2025. PMID: 39985400 Free PMC article.

References

    1. Ioannidis JPA, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336:1413. doi: 10.1136/bmj.a117. - DOI - PMC - PubMed
    1. Viola MG, Diamantopoulos A. Determining the baseline strategy in a cost-effectiveness analysis with treatment sequences. Appl Health Econ Health Policy. 2020;18(1):17–29. doi: 10.1007/s40258-019-00514-2. - DOI - PubMed
    1. Zheng Y, Pan F, Sorensen S. Modeling treatment sequences in pharmacoeconomic models. Pharmacoeconomics. 2017;35(1):15–24. doi: 10.1007/s40273-016-0455-3. - DOI - PubMed
    1. Tosh J, Stevenson M, Akehurst R. Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. Curr Rheumatol Rep. 2014;16(10):447. doi: 10.1007/s11926-014-0447-2. - DOI - PubMed
    1. Messner DA. Evaluating the comparative effectiveness of treatment sequences in oncology: a new approach. J Comp Eff Res. 2015;4(6):537–554. doi: 10.2217/cer.15.47. - DOI - PubMed

LinkOut - more resources